T. Rowe Price Investment Management, Inc. 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:28 pm Sale |
2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS |
T. Rowe Price Investment Management, Inc. | 2,985,272 2.500% |
-3,318,312 (-52.64%) |
Filing |
| 2024-02-14 10:04 am Purchase |
2023-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
T. Rowe Price Investment Management, Inc. | 6,303,584 5.300% |
460,924 (+7.89%) |
Filing |
| 2023-02-14 12:40 pm Purchase |
2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
T. Rowe Price Investment Management, Inc. | 5,842,660 5.300% |
5,842,660 (New Position) |
Filing |